AstraZeneca PLC (AZN.L)
-LSE 3,419.50 
7.00(0.20%) 7:25AM EDT
| Prev Close: | 3,426.50 |
|---|
| Open: | 3,436.50 |
|---|
| Bid: | 3,418.50 |
|---|
| Ask: | 3,420.50 |
|---|
| 1y Target Est: | 49.73 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3,409.50 - 3,444.50 |
|---|
| 52wk Range: | 2,578.50 - 3,487.50 |
|---|
| Volume: | 416,463 |
|---|
| Avg Vol (3m): | 2,361,640 |
|---|
| Market Cap: | 42.74B |
|---|
| P/E (ttm): | 756.36 |
|---|
| EPS (ttm): | 4.52 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in GBp.
Headlines
- BioMarin Gains on Prospects for Experimental Cancer Drugat Bloomberg(Wed, May 22)
- Immune system cancer drugs tipped to be a $35 bln marketat Reuters(Wed, May 22)
- 3 Neil Woodford High-Yield Sharesat Motley Fool(Tue, May 21)
- AstraZeneca closes in on site for new home in Cambridgeat Reuters(Mon, May 20)
- Impax Labs launches generic version of ZomigAP(Fri, May 17)
- Golden Parachutes Face Clampdown in EU Law on Executive Payat Bloomberg(Thu, May 16)
- AstraZeneca accelerates cancer drug testingat Reuters(Thu, May 16)
- AstraZeneca Advances Three Cancer Drugs Into Late-Stage Trialsat Bloomberg(Thu, May 16)
- Cubist bid for Optimer before sale process began-sourcesat Reuters(Wed, May 15)
- Dish lines up banks to finance Sprint bid: sourcesat Reuters(Wed, May 15)
- Dish lines up banks to finance Sprint bid -sourcesat Reuters(Wed, May 15)
- Cubist bid almost $1 billion for Optimer before sale process: sourcesat Reuters(Wed, May 15)
- Cubist bid almost $1 bln for Optimer before sale process-sourcesat Reuters(Wed, May 15)
- A Closer Look at AstraZeneca's Dividend Potentialat Motley Fool(Tue, May 14)
- AstraZeneca, Cubist, Astellas Said to Bid for Optimerat Bloomberg(Tue, May 14)
Key Statistics
| Forward P/E (1 yr): | 6.80 |
|---|
| P/S (ttm): | 158.58 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.30 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.17 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | -1.22 |
|---|
Business Summary
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide.
View More